J
Jeroen Buijsen
Researcher at Maastricht University
Publications - 70
Citations - 4617
Jeroen Buijsen is an academic researcher from Maastricht University. The author has contributed to research in topics: Radiation therapy & Chemoradiotherapy. The author has an hindex of 31, co-authored 62 publications receiving 3493 citations. Previous affiliations of Jeroen Buijsen include Maastricht University Medical Centre.
Papers
More filters
Journal ArticleDOI
Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal Cancer
Monique Maas,Regina G. H. Beets-Tan,Doenja M. J. Lambregts,Guido Lammering,Patty J. Nelemans,Sanne M. E. Engelen,Ronald M. van Dam,Rob L. H. Jansen,Meindert N. Sosef,Jeroen W. A. Leijtens,Karel W.E. Hulsewé,Jeroen Buijsen,Geerard L. Beets +12 more
TL;DR: A wait-and-see policy with strict selection criteria, up-to-date imaging techniques, and follow-up is feasible and results in promising outcome at least as good as that of patients with a pCR after surgery.
Journal ArticleDOI
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
Eva Versteijne,Mustafa Suker,K.B.C. Groothuis,Janine M Akkermans-Vogelaar,Marc G. Besselink,Bert A. Bonsing,Jeroen Buijsen,Olivier R. Busch,Geert-Jan Creemers,Ronald M. van Dam,Ferry A.L.M. Eskens,Sebastiaan Festen,Jan Willem B. de Groot,Bas Groot Koerkamp,Ignace H. J. T. de Hingh,Marjolein Y.V. Homs,Jeanin E. van Hooft,Emile D Kerver,Saskia A C Luelmo,Karen J. Neelis,Joost J. Nuyttens,G. Paardekooper,Gijs A. Patijn,Maurice J.C. van der Sangen,Judith de Vos-Geelen,Johanna W. Wilmink,Aeilko H. Zwinderman,Cornelis J. A. Punt,Casper H.J. van Eijck,Geertjan van Tienhoven +29 more
TL;DR: Although the outcomes of the secondary end points and predefined subgroup analyses suggest an advantage of the neoadjuvant approach, additional evidence is required.
Journal ArticleDOI
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
Annemieke Cats,Edwin P.M. Jansen,Nicole C.T. van Grieken,Karolina Sikorska,Pehr Lind,Marianne Nordsmark,Elma Meershoek-Klein Kranenbarg,Henk Boot,Anouk K. Trip,HA A. Maurits Swellengrebel,Hanneke W. M. van Laarhoven,Hein Putter,Johanna W. van Sandick,Mark I. van Berge Henegouwen,Henk H. Hartgrink,Harm van Tinteren,Cornelis J.H. van de Velde,Marcel Verheij,Frits van Coevorden,Steven Vanhoutvin,Maarten C.C.M. Hulshof,Olaf Jl Loosveld,A (Bert) Jan Ten Tije,Frans L. G. Erdkamp,Fabiënne A. R. M. Warmerdam,Donald L. van der Peet,Henk M.W. Verheul,Djamila Boerma,Maartje Los,Annerie Slot,Danny Houtsma,Johanna E.A. Portielje,Reinoud J. B. Blaisse,Ernst Jan Spillenaar Bilgen,Marco B Polée,Maud M. Geenen,Jeffrey P.B.M. Braak,Karen J. Neelis,Marije Slingerland,Rob L. H. Jansen,Jeroen Buijsen,Aart Beeker,Quirijn A. J. Eijsbouts,Johanna Mgh Van Riel,Tom Rozema,Dick Johan van Spronsen,Jetske M. Meerum Terwogt,Bea C Tanis,Adelheid Me Van der Torren-Conze,Richard Van Hilligersberg,Miriam Koopman,Marien O Den Boer,Geert-Jan Creemers,Maurice J.C. van der Sangen,Marjolein Em Rentinck,H Pieter van den Berg,Ge Jpm Jonkers,Diane Grootenboers,Annelie Je Vulink,Sjoerd Hovenga,Huub van der Mijle,Arnold Baars,A. Haringhuizen,Marije Ie Appels,Ron C Rietbroek,Ellen M Hendriksen,Marie-Cecile Jc Legdeur,Daan Ten Bokkel Huinink,O Aart Van Dobbenburgh,Jitty M Smit,Aart Van Bochove,Gerrit-Jan Veldhuis,Erik W Muller,Johannes J. Bonenkamp,Pètra M Braam,Jaap De Boer,Henk K Van Halteren,Fransje Aa Valster,Alex L. T. Imholz,Marjan A Van Dijk,Ate van der Gaast,J (Hans)-Martin Mb Otten,Heleen M. Ceha,Bengt Glimelius,Cecillia Lagerbäck,Mats Perman,Anders Johnsson,David Borg,Niels H Nielsen,Andrzej Piwowar,Mattias Elmlund,Helene Hörberg,Per Edlund,Bengt Johansson,Petra Flygare,Marie Louise Jespersen +95 more
TL;DR: This investigator-initiated, open-label, randomised phase 3 trial aimed to compare perioperative chemotherapy with preoperative chemotherapy and postoperative chemoradiotherapy in patients with resectable gastric adenocarcinoma.
Journal ArticleDOI
PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes.
Angela van Baardwijk,Geert Bosmans,Liesbeth J. Boersma,Jeroen Buijsen,S Wanders,Monique Hochstenbag,Robert-Jan van Suylen,Andre Dekker,Cary Dehing-Oberije,Ruud Houben,Søren M. Bentzen,Marinus J.P.G. van Kroonenburgh,Philippe Lambin,Dirk De Ruysscher +13 more
TL;DR: In this article, the authors compared source-to-background ratio-based auto-delineation with pathology in non-small-cell lung cancer (NSCLC) and investigated whether auto-Delineation reduces the interobserver variability compared with manual PET-CT-based gross tumor volume (GTV) delineation.
Journal ArticleDOI
Outcomes and patterns of failure in solitary plasmacytoma: A multicenter Rare Cancer Network study of 258 patients
Mahmut Ozsahin,Richard W. Tsang,Philip Poortmans,Yazid Belkacemi,Michel Bolla,Fazilet Oner Dincbas,Christine Landmann,Bernard Castelain,Jeroen Buijsen,Jürgen Curschmann,Sidney P. Kadish,Anna Kowalczyk,Yavuz Anacak,Josef Hammer,Tan D. Nguyen,Gabriela Studer,Rachel A Cooper,Meric Sengoz,Luciano Scandolaro,Abderrahim Zouhair +19 more
TL;DR: Progression to MM remains the main problem, but patients with extramedullary SP had the best outcomes, especially when treated with moderate-dose RT, and Chemotherapy and/or novel therapies should be investigated for bone or bulky extrameastern SP.